UCB SA (UCB) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The companys key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohns disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinsons disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA (UCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 6
List of Figures 7
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
UCB SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19
Venture Financing 20
Syndesi Therapeutics Raises USD21 Million in Series A Financing 20
Element Genomics Raises USD5 Million in Venture Financing 22
Lumos Pharma Raises USD34 Million in Series B Financing Round 23
Clementia Pharma Secures USD60 Million Venture Financing 25
Clementia Pharma Raises USD60 Million in Venture Financing 27
Dermira Raises USD51 Million In Series C Venture Financing 29
Private Equity 31
Paragon Partners to Acquire UCB Innere Medizin from UCB 31
Partnerships 32
Dr. Reddys Laboratories Enters into Distribution Agreement with UCB 32
Q-State Biosciences Enters into Research Agreement with UCB 33
NovAliX Enters into Agreement with UCB Biopharma 34
MC10 Enters into Agreement with UCB 35
MRC Technology, UCB and University of Leicester Enter into Agreement 36
UCB Enters into Research Agreement with Baylor College of Medicine 37
Evotec Partners with UCB 38
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 39
Beryllium Enters into Agreement with UCB to Develop Drug Targets 40
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 41
Sanofi Enters Into Agreement With UCB For Drug Discovery 42
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 43
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 44
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 45
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 46
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 47
UCB Enters Into Research Agreement With Five Prime Therapeutics 48
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 49
biOasis Technologies Enters Into Research Agreement With UCB 50
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 51
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 52
UCB Enters Into Co-Development Agreement With Harvard University 53
UCB Enters Into Co-Development Agreement With Imperial College London 54
UCB Enters Into Co-Development Agreement With Oxford University 55
Nodality Enters Into Co-Developement Agreement With UCB Pharma 56
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 57
Otsuka Pharma Amends Co-Development Agreement With UCB 59
Licensing Agreements 61
UCB Enters into Licensing Agreement with Five Prime Therapeutics 61
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 62
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 63
Zai Lab Enters into Licensing Agreement with UCB 64
UCB Exercises Option for Licensing Agreement with Oncodesign 65
Kings College Enters into Licensing Agreement with UCB 66
Kings College London Enters Into Licensing Agreement with UCB 67
Neuropore Therapies Enters into Licensing Agreement with UCB 68
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 69
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 70
Equity Offering 71
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 71
Syndesi Therapeutics Spins Out from UCB 73
Dermira Raises USD7.5 Million in Private Placement of Shares 74
Wilex Completes Private Placement Of Shares For US$12.4 Million 76
Debt Offering 77
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 77
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 78
UCB Completes Public Offering Of Bonds For US$326 Million 79
Asset Transactions 80
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 80
Dr Reddys Labs Acquires Brands Portfolio of UCB for USD128 Million 81
Exemed Pharma Acquires Indian Production Facility of UCB 82
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 83
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 84
Acquisition 85
UCB Acquires Element Genomics 85
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 86
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 87
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 88
UCB Acquires 51% Stake In Meizler Biopharma 90
UCB SA - Key Competitors 91
UCB SA - Key Employees 92
UCB SA - Locations And Subsidiaries 93
Head Office 93
Other Locations & Subsidiaries 93
Joint Venture 96
Recent Developments 97
Financial Announcements 97
Jul 26, 2018: UCB half year report 2018: UCB continues its growth path 97
Apr 25, 2018: UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook 99
Feb 22, 2018: UCB Full Year Report 2017 101
Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 102
Jul 27, 2017: UCB with a strong first half year 2017 giving rise to the financial outlook for 2017 103
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 106
Corporate Communications 107
Mar 24, 2017: UCB General Meeting on 27 April 2017 107
Government and Public Interest 108
Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA] 108
May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 109
Product News 110
09/21/2017: UCBs anti-epileptic drug VIMPAT (lacosamide) receives EU approval for paediatric use 110
08/25/2017: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients 111
07/20/2017: UCB Pharma Receives CHMP Positive Opinion for Vimpat 112
Product Approvals 113
Sep 01, 2017: Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg 113
Mar 13, 2017: UCB Pharmas Vimpat Rejects For Use Within NHS Scotland 114
Clinical Trials 115
Apr 26, 2017: Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 115
Other Significant Developments 116
Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 116
Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 117
Appendix 118
Methodology 118
About GlobalData 118
Contact Us 118
Disclaimer 118

List Of Tables


UCB SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19
Syndesi Therapeutics Raises USD21 Million in Series A Financing 20
Element Genomics Raises USD5 Million in Venture Financing 22
Lumos Pharma Raises USD34 Million in Series B Financing Round 23
Clementia Pharma Secures USD60 Million Venture Financing 25
Clementia Pharma Raises USD60 Million in Venture Financing 27
Dermira Raises USD51 Million In Series C Venture Financing 29
Paragon Partners to Acquire UCB Innere Medizin from UCB 31
Dr. Reddys Laboratories Enters into Distribution Agreement with UCB 32
Q-State Biosciences Enters into Research Agreement with UCB 33
NovAliX Enters into Agreement with UCB Biopharma 34
MC10 Enters into Agreement with UCB 35
MRC Technology, UCB and University of Leicester Enter into Agreement 36
UCB Enters into Research Agreement with Baylor College of Medicine 37
Evotec Partners with UCB 38
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 39
Beryllium Enters into Agreement with UCB to Develop Drug Targets 40
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 41
Sanofi Enters Into Agreement With UCB For Drug Discovery 42
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 43
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 44
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 45
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 46
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 47
UCB Enters Into Research Agreement With Five Prime Therapeutics 48
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 49
biOasis Technologies Enters Into Research Agreement With UCB 50
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 51
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 52
UCB Enters Into Co-Development Agreement With Harvard University 53
UCB Enters Into Co-Development Agreement With Imperial College London 54
UCB Enters Into Co-Development Agreement With Oxford University 55
Nodality Enters Into Co-Developement Agreement With UCB Pharma 56
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 57
Otsuka Pharma Amends Co-Development Agreement With UCB 59
UCB Enters into Licensing Agreement with Five Prime Therapeutics 61
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 62
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 63
Zai Lab Enters into Licensing Agreement with UCB 64
UCB Exercises Option for Licensing Agreement with Oncodesign 65
Kings College Enters into Licensing Agreement with UCB 66
Kings College London Enters Into Licensing Agreement with UCB 67
Neuropore Therapies Enters into Licensing Agreement with UCB 68
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 69
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 70
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 71
Syndesi Therapeutics Spins Out from UCB 73
Dermira Raises USD7.5 Million in Private Placement of Shares 74
Wilex Completes Private Placement Of Shares For US$12.4 Million 76
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 77
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 78
UCB Completes Public Offering Of Bonds For US$326 Million 79
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 80
Dr Reddys Labs Acquires Brands Portfolio of UCB for USD128 Million 81
Exemed Pharma Acquires Indian Production Facility of UCB 82
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 83
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 84
UCB Acquires Element Genomics 85
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 86
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 87
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 88
UCB Acquires 51% Stake In Meizler Biopharma 90
UCB SA, Key Competitors 91
UCB SA, Key Employees 92
UCB SA, Subsidiaries 93
UCB SA, Joint Venture 96

List Of Figures


UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13

UCB SA (UCB) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of

USD 250 View Report

UCB SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

UCB SA Company Profile is a detailed strategic and analytical report on UCB SA. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

UCB SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

UCB SA Company Profile is a detailed strategic and analytical report on UCB SA. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

UCB SA (UCB) - Medical Equipment - Deals and Alliances Profile.

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available